{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:16:11Z","timestamp":1795043771397,"version":"4.10.2"},"reference-count":48,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"4","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>This study undertakes a comprehensive comparison of five different interventions for the treatment of type-1 retinopathy of prematurity (ROP) and aggressive posterior ROP (APROP), offering insights into their relative efficacies and contributing to better clinical decision making. The aim of this study was to compare the efficacy of intravitreal aflibercept (IVA), intravitreal bevacizumab (IVB), intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), and laser therapy in treating these conditions. We conducted a search for relevant randomized controlled trials (RCTs) in databases, namely, PubMed, Embase, Cochrane Library, Web of Science, and Ovid, focusing on these five treatment modalities for ROP. The quality of the included studies was evaluated using the Cochrane Risk of Bias Assessment Tool, and data analysis was performed using STATA software. The results from our network meta-analysis (NMA) indicated that IVA significantly prolonged the interval between initial treatment and relapse in patients, with a surface under the cumulative ranking curve (SUCRA) value of 99.1%. Additionally, patients in the IVB group had a significantly higher spherical equivalent refraction (SER) after surgery, with a SUCRA value of 84.4%. Furthermore, IVR was the most effective in reducing the duration of peripheral retinal vascularization, with a SUCRA value of 95.6%. However, no statistically significant differences were found in relapse rates among the five treatment options. Our analysis concludes that intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drug monotherapy generally offer better outcomes than laser treatment for ROP. Nonetheless, additional RCTs are necessary to further evaluate the safety of anti-VEGF agents.<\/jats:p>","DOI":"10.17305\/bb.2023.9829","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:12:47Z","timestamp":1700151167000},"page":"676-687","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis"],"prefix":"10.17305","volume":"24","author":[{"given":"Yufei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"161810","doi-asserted-by":"crossref","unstructured":"Dogra M, Katoch D, Dogra M. An update on retinopathy of prematurity (ROP). Ind J Pediatr. 2017;84(12):930-6. doi:10.1007\/s12098-017-2404-3","DOI":"10.1007\/s12098-017-2404-3"},{"key":"161811","doi-asserted-by":"crossref","unstructured":"Morrison D, Shaffer J, Ying G-S, Binenbaum G. Ocular complications following treatment in the postnatal growth and retinopathy of prematurity (G-ROP) study. J AAPOS. 2018;22(2):128-33. doi:10.1016\/j.jaapos.2017.12.005","DOI":"10.1016\/j.jaapos.2017.12.005"},{"key":"161812","doi-asserted-by":"crossref","unstructured":"Quimson S. Retinopathy of prematurity: pathogenesis and current treatment options. Neonatal Netw. 2015;34(5):284-7. doi:10.1891\/0730-0832.34.5.284","DOI":"10.1891\/0730-0832.34.5.284"},{"key":"161813","doi-asserted-by":"crossref","unstructured":"Tan Q, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS One. 2019;14(12):e0225643. doi:10.1371\/journal.pone.0225643","DOI":"10.1371\/journal.pone.0225643"},{"key":"161814","doi-asserted-by":"crossref","unstructured":"Chen P, Rossin E, Vavvas D. Aflibercept for retinopathy of prematurity: a systematic review and meta-analysis. Ophthalmic Surg Lasers Imaging Retina. 2021;52(12):673-81. doi:10.3928\/23258160-20211124-01","DOI":"10.3928\/23258160-20211124-01"},{"key":"161815","doi-asserted-by":"crossref","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl E, Wackernagel W, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015;10(6):e0129383. doi:10.1371\/journal.pone.0129383","DOI":"10.1371\/journal.pone.0129383"},{"key":"161816","doi-asserted-by":"crossref","unstructured":"Taher N, Ghaddaf A, Al-Ghamdi S, Homsi J, Al-Harbi B, Alomari L, et al. Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity: a systematic review and meta-analysis. Front Med. 2022;9:884608. doi:10.3389\/fmed.2022.884608","DOI":"10.3389\/fmed.2022.884608"},{"key":"161817","doi-asserted-by":"crossref","unstructured":"Wang S, Zhang G. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis. Int J Ophthalmol. 2020;13(5):806-15. doi:10.18240\/ijo.2020.05.17","DOI":"10.18240\/ijo.2020.05.17"},{"key":"161818","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142. doi:10.1002\/14651858.Ed000142","DOI":"10.1002\/14651858.ED000142"},{"key":"161819","doi-asserted-by":"crossref","unstructured":"Georgiou P, Tan E, Gouvas N, Antoniou A, Brown G, Nicholls R, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol. 2009;10(11):1053-62. doi:10.1016\/s1470-2045(09)70224-4","DOI":"10.1016\/S1470-2045(09)70224-4"},{"key":"161820","doi-asserted-by":"crossref","unstructured":"Jackson D, Riley R, White I. Multivariate meta-analysis: potential and promise. Stat Med. 2011;30:2481-98. doi:10.1002\/sim.4172","DOI":"10.1002\/sim.4172"},{"key":"161821","doi-asserted-by":"crossref","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. doi:10.1186\/2046-4053-4-1","DOI":"10.1186\/2046-4053-4-1"},{"key":"161822","doi-asserted-by":"crossref","unstructured":"Vats D, Flegal J, Jones G. Multivariate output analysis for Markov chain Monte Carlo. Biometrika. 2019;106:321-37. doi:10.1093\/biomet\/asz002","DOI":"10.1093\/biomet\/asz002"},{"key":"161823","doi-asserted-by":"crossref","unstructured":"Salanti G, Ades A, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-71. doi:10.1016\/j.jclinepi.2010.03.016","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"161824","doi-asserted-by":"crossref","unstructured":"Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One,. 2013;8(10):e76654. doi:10.1371\/journal.pone.0076654","DOI":"10.1371\/journal.pone.0076654"},{"key":"161825","doi-asserted-by":"crossref","unstructured":"Wang Z, Carter R. Ranking of the most effective treatments for cardiovascular disease using SUCRA: is it as sweet as it appears?. Eur J Prev Cardiol,. 2018;25(8):842-3. doi:10.1177\/2047487318767199","DOI":"10.1177\/2047487318767199"},{"key":"161826","doi-asserted-by":"crossref","unstructured":"Marotta N, Demeco A, Moggio L, Marinaro C, Pino I, Barletta M, et al. Comparative effectiveness of breathing exercises in patients with chronic obstructive pulmonary disease. Complement Ther Clin Pract. 2020;41:101260. doi:10.1016\/j.ctcp.2020.101260","DOI":"10.1016\/j.ctcp.2020.101260"},{"key":"161827","doi-asserted-by":"crossref","unstructured":"Khera R, Murad M, Chandar A, Dulai P, Wang Z, Prokop L, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424-34. doi:10.1001\/jama.2016.7602","DOI":"10.1001\/jama.2016.7602"},{"key":"161828","doi-asserted-by":"crossref","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmologica. 2020;98(8):e1004-e8. doi:10.1111\/aos.14460","DOI":"10.1111\/aos.14460"},{"key":"161829","doi-asserted-by":"crossref","unstructured":"Ekinci D, \u00c7elik K. Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2020;57(1):54-60. doi:10.3928\/01913913-20191104-01","DOI":"10.3928\/01913913-20191104-01"},{"key":"161830","doi-asserted-by":"crossref","unstructured":"Geloneck M, Chuang A, Clark W, Hunt M, Norman A, Packwood E, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327-33. doi:10.1001\/jamaophthalmol.2014.2772","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"key":"161831","doi-asserted-by":"crossref","unstructured":"Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS. 2015;19(2):140-4. doi:10.1016\/j.jaapos.2015.01.009","DOI":"10.1016\/j.jaapos.2015.01.009"},{"key":"161832","doi-asserted-by":"crossref","unstructured":"Kabata\u015f EU, Kurtul BE, \u00d6zer PA, Kabata\u015f N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab, and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054-8. doi:10.1080\/02713683.2016.1264607","DOI":"10.1080\/02713683.2016.1264607"},{"key":"161833","doi-asserted-by":"crossref","unstructured":"Kimyon S, Mete A. Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting Zone 1. Ophthalmologica. 2018;240(2):99-105. doi:10.1159\/000489023","DOI":"10.1159\/000489023"},{"key":"161834","doi-asserted-by":"crossref","unstructured":"Kuo H, Sun I, Chung M, Chen Y. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy. Ophthalmologica. 2015;234(4):211-17. doi:10.1159\/000439182","DOI":"10.1159\/000439182"},{"key":"161835","doi-asserted-by":"crossref","unstructured":"Lin C, Tsai Y. Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clin Ophthalmol. 2016;10:1323-7. doi:10.2147\/opth.S110717","DOI":"10.2147\/OPTH.S110717"},{"key":"161836","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner H, Kennedy K, Chuang A. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-15. doi:10.1056\/NEJMoa1007374","DOI":"10.1056\/NEJMoa1007374"},{"key":"161837","doi-asserted-by":"crossref","unstructured":"Riazi-Esfahani H, Mahmoudi A, Sanatkar M, Farahani A, Bazvand F. Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity. Int J Retina Vitreous. 2021;7(1):60. doi:10.1186\/s40942-021-00334-4","DOI":"10.1186\/s40942-021-00334-4"},{"key":"161838","doi-asserted-by":"crossref","unstructured":"Simmons M, Wang J, Leffler J, Li S, Morale S, de la Cruz A, et al. Longitudinal development of refractive error in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity. Transl Vis Sci Technol. 2021;10(4):14. doi:10.1167\/tvst.10.4.14","DOI":"10.1167\/tvst.10.4.14"},{"key":"161839","doi-asserted-by":"crossref","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds J, Chiang M, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomized controlled trial. Lancet. 2019;394(10208):1551-9. doi:10.1016\/s0140-6736(19)31344-3","DOI":"10.1016\/S0140-6736(19)31344-3"},{"key":"161840","doi-asserted-by":"crossref","unstructured":"Sukgen E, Ko\u00e7luk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefe\u2019s Arch Clin Exp Ophthalmol. 2019;257(1):49-55. doi:10.1007\/s00417-018-4168-5","DOI":"10.1007\/s00417-018-4168-5"},{"key":"161841","doi-asserted-by":"crossref","unstructured":"Demir S, Yesiltas S, Karapapak M, Ozyurek E, Bulbul A, Uslu H, et al. Evaluation of the effect of different treatment management on refractive outcomes in severe retinopathy of prematurity. Sisli Etfal Hastanesi Tip Bulteni. 2021;55(4):545-50. doi:10.14744\/semb.2021.34966","DOI":"10.14744\/SEMB.2021.34966"},{"key":"161842","doi-asserted-by":"crossref","unstructured":"Wu Z, Zhao J, Lam W, Yang M, Chen L, Huang X, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomized controlled trial. Brit J Ophthalmol. 2022;106(7):975-9. doi:10.1136\/bjophthalmol-2020-318026","DOI":"10.1136\/bjophthalmol-2020-318026"},{"key":"161843","doi-asserted-by":"crossref","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710-7. doi:10.1097\/iae.0000000000001241","DOI":"10.1097\/IAE.0000000000001241"},{"key":"161844","doi-asserted-by":"crossref","unstructured":"Zhao J, Wu Z, Lam W, Yang M, Chen L, Zheng L, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. Brit J Ophthalmol. 2020;104(11):1556-60. doi:10.1136\/bjophthalmol-2019-315520","DOI":"10.1136\/bjophthalmol-2019-315520"},{"key":"161845","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen S. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Brit J Ophthalmol. 2020;104(5):691-6. doi:10.1136\/bjophthalmol-2019-314610","DOI":"10.1136\/bjophthalmol-2019-314610"},{"key":"161846","doi-asserted-by":"crossref","unstructured":"Gunay M, Sukgen E, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462-9. doi:10.1080\/02713683.2016.1196709","DOI":"10.1080\/02713683.2016.1196709"},{"key":"161847","doi-asserted-by":"crossref","unstructured":"Harder B, Schlichtenbrede F, von Baltz S, Jendritza W, Jendritza B, Jonas J. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119-24.e1. doi:10.1016\/j.ajo.2013.01.014","DOI":"10.1016\/j.ajo.2013.01.014"},{"key":"161848","doi-asserted-by":"crossref","unstructured":"Hwang C, Hubbard G, Hutchinson A, Lambert S. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008-15. doi:10.1016\/j.ophtha.2014.12.017","DOI":"10.1016\/j.ophtha.2014.12.017"},{"key":"161849","doi-asserted-by":"crossref","unstructured":"Kang H, Choi E, Byeon S, Kim S, Koh H, Lee S, et al. Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. Korean J Ophthalmol. 2018;32(6):451-8. doi:10.3341\/kjo.2018.0011","DOI":"10.3341\/kjo.2018.0011"},{"key":"161850","doi-asserted-by":"crossref","unstructured":"Lee Y, See L, Chang S, Wang N, Hwang Y, Lai C, et al. Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol. 2018;192:20-30. doi:10.1016\/j.ajo.2018.05.002","DOI":"10.1016\/j.ajo.2018.05.002"},{"key":"161851","doi-asserted-by":"crossref","unstructured":"Lu X, Zeng X, Chen M, Fan Z, Zheng L, Tian Y, et al. Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection. Graefe\u2019s Arch Clin Exp Ophthalmol. 2022;260(10):3213-19. doi:10.1007\/s00417-022-05663-0","DOI":"10.1007\/s00417-022-05663-0"},{"key":"161852","doi-asserted-by":"crossref","unstructured":"Sukgen E, Atalay H, \u00d6zdek \u015e. Long-term effects of anti-vegf monotherapy for retinopathy of prematurity on the retinal and refractive development of the eye. Retina. 2022;42(11):2194-202. doi:10.1097\/iae.0000000000003590","DOI":"10.1097\/IAE.0000000000003590"},{"key":"161853","doi-asserted-by":"crossref","unstructured":"Jin E, Yin H, Li X, Zhao M. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina. 2018;38(8):1595-604. doi:10.1097\/iae.0000000000001763","DOI":"10.1097\/IAE.0000000000001763"},{"key":"161854","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez C, D\u00edaz C, Garret\u00f3n C. Anti-vascular endothelial growth factor (VEGF) drugs compared to laser photocoagulation for the treatment of type 1 retinopathy of prematurity. Medwave. 2022;22(1):e8507. doi:10.5867\/medwave.2022.01.8507","DOI":"10.5867\/medwave.2022.01.8507"},{"key":"161855","doi-asserted-by":"crossref","unstructured":"Kong Q, Ming W, Mi X. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. BMJ Open. 2021;11(2):e042384. doi:10.1136\/bmjopen-2020-042384","DOI":"10.1136\/bmjopen-2020-042384"},{"key":"161856","doi-asserted-by":"crossref","unstructured":"Beccasio A, Mignini C, Caricato A, Iaccheri B, Di Cara G, Verrotti A, et al. New trends in intravitreal anti-VEGF therapy for ROP. Eur J Ophthalmol. 2022;32(3):1340-51. doi:10.1177\/11206721211073405","DOI":"10.1177\/11206721211073405"},{"key":"161857","doi-asserted-by":"crossref","unstructured":"Tran K, Cernichiaro-Espinosa L, Berrocal A. Management of retinopathy of prematurity\u2014Use of anti-VEGF therapy. Asia\u2013Pacific J Ophthalmol. 2018;7(1):56-62. doi:10.22608\/apo.2017436","DOI":"10.22608\/APO.2017436"}],"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/9829\/3106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/9829\/3106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:18:30Z","timestamp":1795040310000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/9829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,28]]}},"URL":"https:\/\/doi.org\/10.17305\/bb.2023.9829","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}